DE60227763D1 - Verwendung eines natriuretischen peptids vom b-typ als prognostischer indikator bei akuten koronaren syndromen - Google Patents
Verwendung eines natriuretischen peptids vom b-typ als prognostischer indikator bei akuten koronaren syndromenInfo
- Publication number
- DE60227763D1 DE60227763D1 DE60227763T DE60227763T DE60227763D1 DE 60227763 D1 DE60227763 D1 DE 60227763D1 DE 60227763 T DE60227763 T DE 60227763T DE 60227763 T DE60227763 T DE 60227763T DE 60227763 D1 DE60227763 D1 DE 60227763D1
- Authority
- DE
- Germany
- Prior art keywords
- acute coronary
- wave
- natriuretic peptide
- coronary syndrome
- type natriuretic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/835,298 US7632647B2 (en) | 2001-04-13 | 2001-04-13 | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
PCT/US2002/011441 WO2002083913A1 (en) | 2001-04-13 | 2002-04-11 | Use of b-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60227763D1 true DE60227763D1 (de) | 2008-09-04 |
Family
ID=25269150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60227763T Expired - Lifetime DE60227763D1 (de) | 2001-04-13 | 2002-04-11 | Verwendung eines natriuretischen peptids vom b-typ als prognostischer indikator bei akuten koronaren syndromen |
Country Status (11)
Country | Link |
---|---|
US (3) | US7632647B2 (de) |
EP (2) | EP1983058B1 (de) |
JP (2) | JP3749225B2 (de) |
AT (1) | ATE402266T1 (de) |
AU (2) | AU2002252636B2 (de) |
CA (1) | CA2412648C (de) |
DE (1) | DE60227763D1 (de) |
DK (1) | DK1311701T3 (de) |
ES (1) | ES2310590T3 (de) |
NZ (1) | NZ523210A (de) |
WO (1) | WO2002083913A1 (de) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6991907B1 (en) * | 1995-04-18 | 2006-01-31 | Biosite, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
US6627404B1 (en) * | 1995-04-18 | 2003-09-30 | Biosite, Inc. | Methods for improving the recovery of troponin I and T in membranes, filters and vessels |
US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040176914A1 (en) * | 2001-04-13 | 2004-09-09 | Biosite Incorporated | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
DE60235416D1 (de) * | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen |
JP2005522669A (ja) * | 2001-08-20 | 2005-07-28 | バイオサイト インコーポレイテッド | 卒中および脳損傷の診断マーカーおよびその使用方法 |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US6461828B1 (en) | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
MXPA03004105A (es) | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
SG159387A1 (en) * | 2002-11-26 | 2010-03-30 | Biocon Ltd In | Modified natriuretic compounds, conjugates, and uses thereof |
JP2006526140A (ja) * | 2002-12-24 | 2006-11-16 | バイオサイト インコーポレイテッド | 鑑別診断のためのマーカーおよびその使用方法 |
WO2004082639A2 (en) * | 2003-03-19 | 2004-09-30 | Baylor College Of Medicine | Detecting coronary artery disease with bnp during stress testing |
US7341838B2 (en) * | 2003-04-17 | 2008-03-11 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US20060177870A1 (en) * | 2003-04-28 | 2006-08-10 | Ciphergen Biosystems, Inc | Immunoassays |
US20070037208A1 (en) * | 2003-05-29 | 2007-02-15 | Foote Robert S | Method for detecting cardiac ischemia via changes in b-natriuretic peptide levels |
US7632234B2 (en) * | 2003-08-29 | 2009-12-15 | Medtronic, Inc. | Implantable biosensor devices for monitoring cardiac marker molecules |
EP1673465A4 (de) * | 2003-09-29 | 2008-04-30 | Biosite Inc | Verfahren und zusammensetzungen zur sepsisdiagnose |
DE10355731A1 (de) | 2003-11-28 | 2005-06-30 | Roche Diagnostics Gmbh | Analytischer Sandwichtest zur Bestimmung von NT-proBNP |
EP1698058A4 (de) * | 2003-12-18 | 2009-09-23 | Inverness Medical Switzerland | Überwachungsverfahren und -vorrichtung |
GB0329288D0 (en) | 2003-12-18 | 2004-01-21 | Inverness Medical Switzerland | Monitoring method and apparatus |
ATE403157T1 (de) * | 2004-03-15 | 2008-08-15 | Hoffmann La Roche | Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung |
US7223237B2 (en) * | 2004-04-22 | 2007-05-29 | Pacesetter, Inc. | Implantable biosensor and methods for monitoring cardiac health |
JP4838794B2 (ja) * | 2004-06-15 | 2011-12-14 | エフ.ホフマン−ラ ロシュ アーゲー | 心臓毒性医薬の結果として心血管合併症に罹患するリスクを診断するための心臓ホルモンの使用 |
EP1778874B1 (de) * | 2004-07-30 | 2011-11-23 | Adeza Biomedical Corporation | Onkofetales fibronektin als zervixkarzinom-marker |
US20060084114A1 (en) * | 2004-10-15 | 2006-04-20 | Yeo Kiang-Tech J | Method for detecting cardiac collateral formation |
US20080207505A1 (en) * | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
EP1691200A1 (de) * | 2005-02-14 | 2006-08-16 | F. Hoffmann-La Roche Ag | Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung |
EP1986012B1 (de) * | 2005-01-24 | 2012-06-06 | F. Hoffmann-La Roche AG | Verwendung von Bnp-typ für die Ermittlung von Herzversagen Risiken als Folge der Volumenüberlastung |
US7432107B2 (en) * | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
US7731965B2 (en) * | 2005-02-17 | 2010-06-08 | Abbott Lab | Human ring specific BNP antibodies |
US7300494B2 (en) * | 2005-02-24 | 2007-11-27 | Hamilton Sundstrand Corporation | On-board inert gas generation system with compressor surge protection |
US7769451B2 (en) | 2005-04-28 | 2010-08-03 | Medtronic, Inc. | Method and apparatus for optimizing cardiac resynchronization therapy |
EP1722232A1 (de) * | 2005-05-09 | 2006-11-15 | F.Hoffmann-La Roche Ag | Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion |
JP5090348B2 (ja) * | 2005-07-29 | 2012-12-05 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 心疾患の診断、処置及び治療中の心臓ナトリウム利尿ペプチドの監視 |
JP5364378B2 (ja) * | 2005-11-09 | 2013-12-11 | アボット・ラボラトリーズ | ヒトbnp免疫特異的抗体 |
US7939069B2 (en) | 2005-11-09 | 2011-05-10 | Abbott Laboratories | Human BNP immunospecific antibodies |
EP2005168A4 (de) * | 2006-03-09 | 2009-05-20 | Biosite Inc | Verfahren und zusammensetzung zur diagnose von krankheiten der aorta |
EP1835289A1 (de) * | 2006-03-13 | 2007-09-19 | Roche Diagnostics GmbH | Mittel und Verfahren zur Prognose kardiovaskulärer Komplikationen bei Personen mit Osteoporose |
EP1837659B1 (de) * | 2006-03-24 | 2010-06-09 | F. Hoffman-la Roche AG | Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten |
JP6325022B2 (ja) * | 2006-04-04 | 2018-05-16 | シングレックス,インコーポレイテッド | トロポニンの分析のための高感度のシステムおよび方法 |
EP1845379A1 (de) | 2006-04-13 | 2007-10-17 | F. Hoffmann-La Roche AG | Mittel und Verfahren zur Differenzierung kardialer und pulmonaler Ursachen von Atemnot |
US20080118924A1 (en) * | 2006-05-26 | 2008-05-22 | Buechler Kenneth F | Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
EP1882945A1 (de) * | 2006-07-28 | 2008-01-30 | F.Hoffmann-La Roche Ag | Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot |
CA2660691C (en) | 2006-08-04 | 2020-01-14 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
EP1890153A1 (de) | 2006-08-16 | 2008-02-20 | F. Hoffman-la Roche AG | Herztroponin als Indikator für fortgeschrittene Koronararterienerkrankung |
EP1890154B1 (de) * | 2006-08-16 | 2012-07-04 | F. Hoffmann-La Roche AG | Herztroponin als Indikator für fortgeschrittene Koronararterienerkrankung und deren Komplikationen |
US20080050749A1 (en) * | 2006-08-17 | 2008-02-28 | Ildiko Amann-Zalan | Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents |
US20080064045A1 (en) * | 2006-09-07 | 2008-03-13 | Huaiqin Wu | Biomarker fragments for the detection of human BNP |
WO2008030122A1 (en) * | 2006-09-07 | 2008-03-13 | University Of Otago | Biomarkers |
DE602006010705D1 (de) | 2006-09-15 | 2010-01-07 | Roche Diagnostics Gmbh | Biochemische Marker für akute Lungenembolie |
EP1901073A1 (de) | 2006-09-18 | 2008-03-19 | Roche Diagnostics GmbH | Natriuretische Peptide zur Diagnose von Herzkomplikationen infolge von Koronarkatheterisierung |
WO2008060607A2 (en) | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
US8524462B2 (en) * | 2006-11-14 | 2013-09-03 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
JP5306218B2 (ja) * | 2006-11-21 | 2013-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | トロポニンTおよびNT−proBNPの検出に基づく慢性動脈疾患での診断および治療的アプローチの最適化のための手段および方法 |
EP1925943A1 (de) * | 2006-11-21 | 2008-05-28 | F. Hoffman-la Roche AG | Vorrichtungen und Verfahren zur Optimierung von diagnostischen and therapeutischen Ansätzen für chronische Arterienerkrankungen basierend auf dem Nachweis von Troponin T und NT-proBNP. |
EP2115466A4 (de) * | 2006-12-22 | 2010-07-28 | Abbott Lab | Herz-kreislauf-autoimmunkrankheit-testgruppe und verfahren zur verwendung davon |
DK2115477T3 (en) | 2007-01-25 | 2015-08-10 | Hoffmann La Roche | USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE |
EP2101178A1 (de) * | 2008-03-12 | 2009-09-16 | BRAHMS Aktiengesellschaft | Verwendung von Procalcitonin zur Prognose folgender akuter Koronarsyndromen |
EP2174143B1 (de) | 2007-08-03 | 2011-06-22 | B.R.A.H.M.S GmbH | Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit |
EP2031397A1 (de) | 2007-08-30 | 2009-03-04 | F. Hoffmann-La Roche AG | Surfactantproteine B und D bei der Unterscheidung der Ursachen für Atemnot |
EP2210111A1 (de) | 2007-10-10 | 2010-07-28 | Roche Diagnostics GmbH | Natriuretisches peptid/troponin-verhältnis zur beurteilung bereits vorhandener myokard-fehlfunktion bei patienten mit akutem koronarsyndrom |
EP2103943A1 (de) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern |
WO2009141374A1 (en) | 2008-05-21 | 2009-11-26 | F. Hoffmann-La Roche Ag | L-fabp, natriuretic peptides and cardiac troponin in individuals in need for a cardiac therapy |
EP2133696A1 (de) | 2008-06-10 | 2009-12-16 | Eberhardt Spanuth | Sehr geringe Konzentrationen von Troponin I oder T zur Beurteilung eines kardiovaskulären Risikos hinsichtlich der Verabreichung von Entzündungshemmern |
EP2304438A1 (de) * | 2008-06-13 | 2011-04-06 | F. Hoffmann-La Roche AG | Beurteilung von komplikationen bei patienten mit typ-1-diabetes |
EP2318844A1 (de) * | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarkerpanel zur diagnose, überwachung und auswahl der therapie für patienten mit herzinsuffizienz |
EP2321651B1 (de) | 2008-07-23 | 2017-08-23 | F. Hoffmann-La Roche AG | Identifikation von für eine anti-angiogenese-therapie geeigneten personen |
WO2010017972A1 (en) | 2008-08-13 | 2010-02-18 | Roche Diagnostics Gmbh | D-dimer, troponin, nt-probnp for pulmonary embolism |
CN102421917B (zh) | 2009-04-29 | 2014-07-09 | 阿姆斯特丹大学学术医学中心 | 对抗、预防和/或测定心力衰竭或心力衰竭的风险的工具和方法 |
RU2548710C2 (ru) | 2009-09-17 | 2015-04-20 | Ф.Хоффманн-Ля Рош Аг | Мультимаркерная панель для гипертрофии левого желудочка |
WO2011060361A1 (en) * | 2009-11-13 | 2011-05-19 | Bg Medicine, Inc. | Risk factors and prediction of myocardial infarction |
EP3246708A3 (de) | 2009-12-18 | 2018-01-03 | Roche Diagnostics GmbH | Troponins zur prognose von nierenausfall bei herzchirurgiepatienten |
CZ302379B6 (cs) * | 2009-12-22 | 2011-04-20 | Ústav informatiky AV CR, v.v.i. Centrum biomedicínské informatiky | Zpusob stanovení prognózy pacientu s primárním infarktem myokardu a oligonukleotidový cip pro toto stanovení |
ES2535812T3 (es) | 2010-02-12 | 2015-05-18 | Synlab Medizinisches Versorgungszentrum Heidelberg Gmbh | Homoarginina como un marcador biológico para el riesgo de mortalidad |
EP2388594A1 (de) | 2010-05-17 | 2011-11-23 | Roche Diagnostics GmbH | Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung |
WO2012020045A1 (en) | 2010-08-10 | 2012-02-16 | Roche Diagnostics Gmbh | Method for selecting patients with stable coronary artery disease for pci or medical treatment |
EP2367006A1 (de) | 2010-08-24 | 2011-09-21 | Roche Diagnostics GmbH | Mittel und Verfahren auf PLGF-Basis zur Diagnose kardialer Ursachen bei akuten Entzündungen |
CN103080746B (zh) | 2010-08-26 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
EP2439535A1 (de) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnose von Herzerkrankungen im Zusammenhang mit Diabetes und GDF-15 und Troponin als Prädiktor für die Entwicklung von Diabetes mellitus Typ 2 |
EP2447720A1 (de) | 2010-10-26 | 2012-05-02 | Roche Diagnostics GmbH | sFlt1 und Lungenkomplikationen |
EP2383579A1 (de) | 2010-12-17 | 2011-11-02 | F. Hoffmann-La Roche AG | sFlt-1, Kardiotroponine und natriuretische Peptide beim Nachweis einer Therapie mit HER-2-Inhibitoren |
CN102103143B (zh) * | 2011-02-24 | 2013-09-25 | 南京基蛋生物科技有限公司 | 一种双指标检测用胶体金试纸条及其制备方法 |
EP2385373A1 (de) | 2011-07-01 | 2011-11-09 | F. Hoffmann-La Roche AG | Natriuretische Peptide bei der Schwangerschaft |
EP2581040A1 (de) | 2011-10-10 | 2013-04-17 | Roche Diagnostics GmbH | TNT-basiertes Herzhypertrophierisiko im Zusammenhang mit physiologischem Training und Führung in Athleten |
MX347355B (es) | 2011-10-17 | 2017-04-24 | Hoffmann La Roche | Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque. |
CN107064516B (zh) | 2011-12-01 | 2019-08-02 | 霍夫曼-拉罗奇有限公司 | 用于诊断中风的nt-原anp和nt-原bnp |
ES2538226T3 (es) | 2012-01-26 | 2015-06-18 | F. Hoffmann-La Roche Ag | Método para la diferenciación de la insuficiencia cardiaca anterógrada y retrógrada |
EP2650684A1 (de) | 2012-04-10 | 2013-10-16 | Roche Diagniostics GmbH | Diagnose auf Pro-SP-B und NT-proBNP bei Patienten mit Lungenentzündung |
EP2615459A1 (de) | 2012-04-27 | 2013-07-17 | Roche Diagniostics GmbH | Verfahren zur Diagnose von Distalbronchoalveolargewebeschäden in Asthma durch Erkennen von proSP-B |
EP2600155A1 (de) | 2012-06-18 | 2013-06-05 | Roche Diagniostics GmbH | sFlt-1-basierte Diagnose und Überwachung von Schlaganfallpatienten |
EP2597466A1 (de) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Mittel und Verfahren zur proSP-B-basierten Diagnose von Alveolenbeschädigung bei Patienten mit pulmonaler Hypertonie |
EP2597467A1 (de) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Mittel und Verfahren zur proSP-B-basierten Diagnose von Lungenstauung bei Patienten mit akutem Koronarsyndrom |
WO2014009418A1 (en) | 2012-07-10 | 2014-01-16 | Roche Diagnostics Gmbh | TnT, NTproBNP, sFlt-1 for CURB65 IN PNEUMONIA |
EP2895866B1 (de) | 2012-09-12 | 2018-05-30 | Roche Diagnostics GmbH | Identifizierung von patienten mit abnormaler fraktioneller verkürzung |
US20140273273A1 (en) | 2012-11-01 | 2014-09-18 | Christie Mitchell Ballantyne | Biomarkers to improve prediction of heart failure risk |
EP2730923A1 (de) | 2012-11-09 | 2014-05-14 | Roche Diagniostics GmbH | NTproBNP- und cTnT-basierte Therapieanleitung bei Herzversagen |
EP2917736B1 (de) | 2012-11-09 | 2019-12-25 | Roche Diagnostics GmbH | Tnt- oder bnp-basierte diagnose von paroxysmalem vorhofflimmern |
CA2893639C (en) | 2012-12-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | Biomarkers in the selection of therapy of heart failure |
EP2866033A1 (de) | 2013-10-23 | 2015-04-29 | Roche Diagniostics GmbH | Differenzialdiagnose von akuter Atemnot auf Basis von c-terminiertem proSP-B, KL-6 und BNP-Peptiden |
US10274502B2 (en) | 2013-11-04 | 2019-04-30 | The Regents Of The University Of Michigan | Biomarkers and methods for progression prediction for chronic kidney disease |
US20150199491A1 (en) * | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
ES2712201T3 (es) | 2014-01-28 | 2019-05-09 | Hoffmann La Roche | Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B |
EP2916134B1 (de) | 2014-03-05 | 2017-08-16 | Roche Diagnostics GmbH | Verwendung von Seprase zur Differenzialdiagnose von akuter Atemnot |
ES2676553T3 (es) | 2014-03-26 | 2018-07-20 | F. Hoffmann-La Roche Ag | IGFBP7 para el diagnóstico de la disfunción diastólica |
JP2017530356A (ja) | 2014-09-26 | 2017-10-12 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | 心血管系のリスクイベントの予測及びその使用 |
CN108885219A (zh) | 2016-02-04 | 2018-11-23 | 梅坦诺米克斯有限公司 | 用于在受试者中鉴别心力衰竭和肺部疾病的装置和方法 |
ES2817087T3 (es) | 2016-08-04 | 2021-04-06 | Hoffmann La Roche | ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular |
WO2018069487A1 (en) | 2016-10-14 | 2018-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for predicting the risk of loss of renal function in patients with type 2 diabetes |
WO2018127372A1 (en) | 2016-12-13 | 2018-07-12 | Witteman Johanna Cornelia Maria | Detection of transient troponin peaks for diagnosis of subjects at high risk of cardiovascular disease |
EP3360570A1 (de) | 2017-02-13 | 2018-08-15 | Roche Diagnostics GmbH | Monoklonale antikörper für nt-probnp punktmutationen |
US20200264196A1 (en) * | 2017-09-30 | 2020-08-20 | Alfred Health | Method of prognosis |
JP7419341B2 (ja) | 2018-07-31 | 2024-01-22 | エフ. ホフマン-ラ ロシュ アーゲー | 心房細動の評価における循環DKK3(Dickkopf関連タンパク質3) |
WO2020030803A1 (en) | 2018-08-10 | 2020-02-13 | F. Hoffmann-La Roche Ag | Ces-2 (carboxylesterase-2) for the assessment of afib related stroke |
CN113302497A (zh) | 2018-08-16 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 循环tfpi-2(组织因子途径抑制剂2)在心房颤动和抗凝治疗评定中的应用 |
BR112021002728A2 (pt) | 2018-08-17 | 2021-08-10 | F. Hoffmann-La Roche Ag | métodos de avaliação da fibrilação atrial, de auxílio à avaliação da fibrilação atrial, de diagnóstico de insuficiência cardíaca e de predição do risco de hospitalização, método implementado por computador para a avaliação da fibrilação atrial, kit e usos in vitro |
KR20210047304A (ko) | 2018-08-22 | 2021-04-29 | 에프. 호프만-라 로슈 아게 | 심방 세동 평가에서 순환 spon-1 (스폰딘-1) |
WO2020039085A1 (en) | 2018-08-24 | 2020-02-27 | Roche Diagnostics Gmbh | Circulating fgfbp-1 (fibroblast growth factor-binding protein 1) in the assessment of atrial fibrillation and for the prediction of stroke |
WO2020064995A1 (en) | 2018-09-28 | 2020-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
WO2020234451A1 (en) | 2019-05-23 | 2020-11-26 | Roche Diagnostics Gmbh | IGFBP7 RATIO FOR HFpEF |
WO2021165465A1 (en) | 2020-02-20 | 2021-08-26 | Universiteit Maastricht | Detection method of circulating bmp10 (bone morphogenetic protein 10) |
US11419917B2 (en) | 2020-04-07 | 2022-08-23 | Drora Shevy | Treatment for SARS-CoV-2 and other coronaviruses |
EP4222499A1 (de) | 2020-09-30 | 2023-08-09 | F. Hoffmann-La Roche AG | Zirkulierendes total-nt-probnp (glycosyliertes und unglycosyliertes nt-probnp) und sein verhältnis mit nt-probnp (unglycosyliertem nt-probnp) bei der beurteilung von vorhofflimmern |
CN112710852B (zh) * | 2021-03-26 | 2021-08-03 | 上海美迪西生物医药股份有限公司 | 一种gnp多肽的检测试剂盒及检测方法 |
WO2023175152A1 (en) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction |
WO2023175176A1 (en) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Cmybpc marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction |
EP4365598A1 (de) | 2022-11-07 | 2024-05-08 | Hôpitaux Universitaires Saint-Louis-Lariboisière | Schnelle optimierung von oralen herzinsuffizienztherapien mithilfe von nt-probnp-tests |
WO2024100050A1 (en) | 2022-11-07 | 2024-05-16 | Hôpitaux Universitaires Saint-Louis-Lariboisière | Rapid optimization of oral heart failure therapies helped by nt-probnp testing |
WO2024160752A1 (en) | 2023-01-30 | 2024-08-08 | F. Hoffmann-La Roche Ag | Effect induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292636A (en) * | 1986-03-31 | 1994-03-08 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using soluble T cell surface molecules |
US4900662A (en) * | 1987-07-21 | 1990-02-13 | International Immunoassay Laboratories, Inc. | CK-MM myocardial infarction immunoassay |
US5382515A (en) * | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Creative kinase-MB immunoassay for myocardial infarction and reagents |
US5382522A (en) * | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents |
US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
US5422393A (en) | 1988-07-11 | 1995-06-06 | Naturon Pharmaceutical Corporation | Natriuretic hormone |
US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
US5352587A (en) | 1989-06-23 | 1994-10-04 | Genentech, Inc. | Compositions and methods for the synthesis of natriuretic protein receptor B and methods of use |
US5580722A (en) | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
SE8904407L (sv) | 1989-12-29 | 1991-06-30 | Qingpingfeng | Medikament foer behandling av hjaertsvikt |
US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
JPH05504841A (ja) | 1990-09-14 | 1993-07-22 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途 |
CA2027434C (en) * | 1990-10-12 | 1999-01-05 | George Jackowski | Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof |
US5710008B1 (en) * | 1990-10-12 | 1999-09-07 | Spectral Diagnostics Inc | Method and device for diagnosing and distinguishing chest pain in early onset thereof |
US5604105B1 (en) | 1990-10-12 | 1999-08-24 | Spectral Diagnostics Inc | Method and device for diagnosingand distinguishing chest pain in early onset thereof |
US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
DE69228682T2 (de) | 1991-04-10 | 1999-07-01 | Biosite Diagnostics Inc., San Diego, Calif. | "crosstalk"- oder übersprech-inhibitoren und ihre verwendung |
WO1992018866A1 (en) | 1991-04-10 | 1992-10-29 | Biosite Diagnostics Incorporated | Novel conjugates and assays for simultaneous detection of multiple ligands |
US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
US6147688A (en) | 1993-06-28 | 2000-11-14 | Athena Design Systems, Inc. | Method and apparatus for defining and selectively repeating unit image cells |
US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
EP0687120A1 (de) * | 1994-06-09 | 1995-12-13 | ALCATEL BELL Naamloze Vennootschap | Reglementierungsverfahren zur Garantierung von fairem Durchsatz und Anlage zur Durchführung des Verfahrens |
DE69633780T3 (de) * | 1995-04-18 | 2011-05-05 | Biosite Incorporated, San Diego | Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays |
US5795725A (en) | 1995-04-18 | 1998-08-18 | Biosite Diagnostics Incorporated | Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays |
US6627404B1 (en) * | 1995-04-18 | 2003-09-30 | Biosite, Inc. | Methods for improving the recovery of troponin I and T in membranes, filters and vessels |
US6991907B1 (en) * | 1995-04-18 | 2006-01-31 | Biosite, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
EP2292662B1 (de) * | 1996-03-04 | 2014-04-23 | Scios Inc. | Testverfahren und Reagenzien zur Quantifizierung von hBNP |
US5768163A (en) * | 1996-04-15 | 1998-06-16 | Hewlett-Packard | Versatile attachment of handheld devices to a host computing system |
US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
US6156521A (en) | 1997-12-19 | 2000-12-05 | Biosite Diagnostics, Inc. | Methods for the recovery and measurement of troponin complexes |
US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
US6828107B2 (en) * | 1997-09-11 | 2004-12-07 | Shionogi & Co., Ltd. | Immunoassay method for BNP |
US6117644A (en) | 1998-06-04 | 2000-09-12 | Ottawa Heart Institute Research Corporation | Predicting and detecting cardiac allograft rejection |
US6171870B1 (en) * | 1998-08-06 | 2001-01-09 | Spectral Diagnostics, Inc. | Analytical test device and method for use in medical diagnoses |
US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
US6743595B1 (en) * | 1999-01-25 | 2004-06-01 | Metriogene Biosciences Inc. | Method and diagnostic kit for diagnosis of endometriosis |
US6670138B2 (en) | 2000-11-01 | 2003-12-30 | Agy Therapeutics, Inc. | Method of diagnosing ischemic stroke via UCP-2 detection |
US20040176914A1 (en) * | 2001-04-13 | 2004-09-09 | Biosite Incorporated | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
US20040121350A1 (en) * | 2002-12-24 | 2004-06-24 | Biosite Incorporated | System and method for identifying a panel of indicators |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US20040126767A1 (en) * | 2002-12-27 | 2004-07-01 | Biosite Incorporated | Method and system for disease detection using marker combinations |
DE60235416D1 (de) * | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen |
US6627457B2 (en) | 2001-07-30 | 2003-09-30 | Quest Diagnostics Investments Incorporated | Methods for detecting pregnancy |
US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
JP2005522669A (ja) * | 2001-08-20 | 2005-07-28 | バイオサイト インコーポレイテッド | 卒中および脳損傷の診断マーカーおよびその使用方法 |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US6461828B1 (en) | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
US7341838B2 (en) * | 2003-04-17 | 2008-03-11 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US20060105419A1 (en) * | 2004-08-16 | 2006-05-18 | Biosite, Inc. | Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions |
CA2579370A1 (en) * | 2004-09-09 | 2006-03-23 | Biosite Incorporated | Methods and compositions for measuring canine bnp and uses thereof |
US7879979B2 (en) * | 2005-01-21 | 2011-02-01 | Alere International | Arginine analogs, and methods for their synthesis and use |
WO2006135781A2 (en) * | 2005-06-09 | 2006-12-21 | Biosite, Inc. | Methods and compositions for the diagnosis of venous thromboembolic disease |
US20070218498A1 (en) * | 2005-08-30 | 2007-09-20 | Buechler Kenneth F | Use of soluble FLT-1 and its fragments in cardiovascular conditions |
EP2005168A4 (de) * | 2006-03-09 | 2009-05-20 | Biosite Inc | Verfahren und zusammensetzung zur diagnose von krankheiten der aorta |
US20080118924A1 (en) * | 2006-05-26 | 2008-05-22 | Buechler Kenneth F | Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
US8524462B2 (en) * | 2006-11-14 | 2013-09-03 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
WO2008060607A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
-
2001
- 2001-04-13 US US09/835,298 patent/US7632647B2/en active Active
-
2002
- 2002-04-11 CA CA002412648A patent/CA2412648C/en not_active Expired - Lifetime
- 2002-04-11 WO PCT/US2002/011441 patent/WO2002083913A1/en active IP Right Grant
- 2002-04-11 DE DE60227763T patent/DE60227763D1/de not_active Expired - Lifetime
- 2002-04-11 ES ES02721720T patent/ES2310590T3/es not_active Expired - Lifetime
- 2002-04-11 DK DK02721720T patent/DK1311701T3/da active
- 2002-04-11 EP EP08160527.1A patent/EP1983058B1/de not_active Expired - Lifetime
- 2002-04-11 NZ NZ523210A patent/NZ523210A/en not_active IP Right Cessation
- 2002-04-11 EP EP02721720A patent/EP1311701B1/de not_active Revoked
- 2002-04-11 JP JP2002582250A patent/JP3749225B2/ja not_active Expired - Lifetime
- 2002-04-11 AU AU2002252636A patent/AU2002252636B2/en not_active Ceased
- 2002-04-11 AT AT02721720T patent/ATE402266T1/de not_active IP Right Cessation
-
2003
- 2003-03-13 US US10/389,720 patent/US20040171064A1/en not_active Abandoned
-
2004
- 2004-08-18 JP JP2004238278A patent/JP4119408B2/ja not_active Expired - Fee Related
-
2007
- 2007-03-19 AU AU2007201180A patent/AU2007201180B2/en not_active Ceased
-
2010
- 2010-09-02 US US12/874,859 patent/US20110065210A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1983058A1 (de) | 2008-10-22 |
JP3749225B2 (ja) | 2006-02-22 |
ATE402266T1 (de) | 2008-08-15 |
ES2310590T3 (es) | 2009-01-16 |
EP1983058B1 (de) | 2013-12-18 |
JP2004519688A (ja) | 2004-07-02 |
EP1311701A4 (de) | 2005-11-09 |
WO2002083913A1 (en) | 2002-10-24 |
CA2412648C (en) | 2008-10-21 |
AU2007201180B2 (en) | 2010-11-25 |
AU2002252636B2 (en) | 2007-03-08 |
AU2007201180A1 (en) | 2007-04-19 |
EP1311701A1 (de) | 2003-05-21 |
US7632647B2 (en) | 2009-12-15 |
CA2412648A1 (en) | 2002-10-24 |
JP4119408B2 (ja) | 2008-07-16 |
NZ523210A (en) | 2007-04-27 |
US20030022235A1 (en) | 2003-01-30 |
DK1311701T3 (da) | 2008-11-03 |
US20110065210A1 (en) | 2011-03-17 |
US20040171064A1 (en) | 2004-09-02 |
EP1311701B1 (de) | 2008-07-23 |
JP2005049351A (ja) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE402266T1 (de) | Verwendung eines natriuretischen peptids vom b- typ als prognostischer indikator bei akuten koronaren syndromen | |
ATE331960T1 (de) | Diagnose von myokardinfarkt und akutem koronarsyndrom durch kombination von markern | |
Pacher et al. | Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure | |
DE60235416D1 (de) | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen | |
AU2002252636A1 (en) | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes | |
ATE449961T1 (de) | Elektrochemischer teststreifen zur verwendung bei der analyten-bestimmung | |
WO2003016527A3 (en) | Process for the detection of oxidative stress and kit for its implementation | |
ATE382148T1 (de) | Antikörper für apoptosemarker und anwendungsverfahren | |
DE60129314D1 (de) | Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen | |
Melki et al. | Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation | |
PT1173770E (pt) | Metodo para estimar o risco de ulcera peptica | |
DK1664769T3 (da) | Assay til detektion af prohormoner for atrialt natriuretisk peptid og natriuretisk peptid i hjernen | |
Kim et al. | Prediction of long-term mortality based on neutrophil-lymphocyte ratio after percutaneous coronary intervention | |
ATE213777T1 (de) | Assays für homocystein und homocysteindesulfurase aus protozoen trichomonas vaginalis | |
Morawiec et al. | Copeptin as a prognostic marker in acute chest pain and suspected acute coronary syndrome | |
ATE182366T1 (de) | Immunoassays für und monoklonale antikörper gegen prothrombin-aktivierende peptide und ihre abbauprodukte | |
DK1791973T3 (da) | DOT1-histonmethyltransferaser som et target til at identificere terapeutiske midler mod leukæmi | |
EP2071338A3 (de) | Menschliche Diabetes-vermittelnde Proteine | |
WO2002067766A3 (en) | Methods and material for evaluating cardiovascular conditions | |
ATE432364T1 (de) | Sonden zum nachweis von tumorzellen | |
DE69920981D1 (de) | Knorpelresorptionsassays | |
DE50311968D1 (de) | Sensor für einen elektrochemischen messfühler | |
RU2003108463A (ru) | Способ прогнозирования течения острого деструктивного панкреатита | |
WO2001086297A3 (en) | Methods of identifying the activity of gene products | |
AU2003242574A8 (en) | Inhibitors of proteins from the rho-gef family |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: KOCH & SCHIWECK PATENTANWAELTE, 80339 MUENCHEN |